10-QPeriod: Q2 FY2026

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2026

Filed July 30, 2026For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. reported solid financial results for the second quarter and first half of 2026, demonstrating continued revenue growth driven primarily by its collaboration with Sanofi, particularly strong performance from Dupixent. Total revenues increased by 15.2% for the quarter and 17.6% for the six months, reaching $4,290.7 million and $7,896.1 million respectively. Net income for the quarter was $1,296.9 million, a slight decrease from the prior year's $1,391.6 million, resulting in diluted earnings per share of $12.23, down from $12.81. For the first half of the year, net income was $2,024.1 million, a decrease from $2,200.3 million in the prior year, with diluted EPS of $18.95 compared to $20.02. Despite the slight dip in profitability on a per-share basis, the company's balance sheet remains strong, with total assets growing to $41.7 billion. The company continued its commitment to shareholder returns through dividends and share repurchases, signaling confidence in its future performance.

Key Highlights

  • 1Total revenues for Q2 2026 grew 15.2% year-over-year to $4.3 billion, driven by a substantial increase in collaboration revenue, largely from the Sanofi partnership.
  • 2Net income for Q2 2026 was $1.3 billion, leading to diluted EPS of $12.23, a decrease from the prior year's $13.24, reflecting increased operating expenses.
  • 3For the first six months of 2026, total revenues increased 17.6% to $7.9 billion, with net income at $2.0 billion and diluted EPS of $18.95.
  • 4Net product sales saw a modest increase of $11.4 million in Q2, with growth in EYLEA HD and Libtayo offsetting a decline in EYLEA sales due to competitive pressures and the transition to EYLEA HD.
  • 5Sanofi collaboration revenue surged by 73.1% in Q2 to $2.17 billion, primarily due to strong Dupixent sales and a growing profit share percentage.
  • 6Bayer collaboration revenue decreased by 33% in Q2 to $276.2 million, reflecting lower EYLEA sales outside the U.S.
  • 7The company repurchased approximately $1.74 billion of its common stock during the first half of 2026, demonstrating a commitment to returning capital to shareholders.

Frequently Asked Questions

Regeneron's revenue growth in Q2 2026 was primarily driven by a significant increase in collaboration revenue, largely stemming from its partnership with Sanofi. This growth was fueled by strong sales of Dupixent, resulting in a higher share of profits for Regeneron.

Net product sales for EYLEA in the U.S. declined in Q2 2026 compared to the prior year, primarily due to ongoing competitive pressures and the market transition from EYLEA to the newer EYLEA HD. While EYLEA HD sales saw an increase, the overall EYLEA franchise experienced a net decrease in U.S. sales.

Regeneron continues to return capital to shareholders through regular cash dividends and share repurchases. During the first half of 2026, the company repurchased approximately $1.74 billion of its common stock and declared quarterly cash dividends, indicating a commitment to enhancing shareholder value.

Regeneron is involved in various legal proceedings, including patent infringement lawsuits related to EYLEA and other products. While the company believes it has strong defenses, adverse outcomes in these matters could potentially impact its financial results or business operations.